• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Xigduo XR (dapagliflozin + metformin hydrochloride)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Xigduo XR (dapagliflozin + metformin hydrochloride)

  • Profile

Profile

Contact Information

Currently Enrolling Trials

    Show More

    General Information

    Xigduo XR is a combination of dapagliflozin, an inhibitor of sodium-glucose cotransporter 2 (SGLT2), and metformin hydrochloride extended-release, a biguanide. SGLT2 inhibitors remove glucose from the body via the kidneys.

    Xigduo XR is specifically indicated as an adjunct therapy to diet and exercise to improve glycemic control in adults with type II diabetes mellitus when treatment with both dapagliflozin and metformin is appropriate. 

    Xigduo XR is supplied as a tablet for oral administration. The starting dose should be individualized based on each patient’s current treatment regimen. The maximum daily recommended dose is 10 mg for dapagliflozin and 2,000 mg for metformin HCl. Xigduo XR should be taken once daily in the morning with food with gradual dose escalation to reduce the risk of gastrointestinal side effects due to metformin. 

    Clinical Results

    The FDA approval of Xigduo XR was based on four Phase III clinical trials, which provided clinical evidence for the efficacy and safety of dapagliflozin and metformin IR or XR tablets in treatment-naïve patients, in patients inadequately controlled on metformin, as well as compared to a sulfonylurea (glipizide) plus metformin. There have been no clinical studies conducted with Xigduo XR combination tablets. Bioequivalence was demonstrated in healthy adults between Xigduo XR and dapagliflozin plus metformin XR as separate tablets.

    Side Effects

    Adverse reactions associated with the use of Xigduo XR may include, but are not limited to, the following:

    • hypoglycemia
    • gastrointestinal symptoms

    Mechanism of Action

    Xigduo XR combines two anti-hyperglycemic agents with complementary mechanisms of action, dapagliflozin, an inhibitor of sodium-glucose cotransporter 2 (SGLT2), and metformin hydrochloride (HCl) extended-release, a biguanide, in a once-daily oral tablet. SGLT2 inhibitors are a class of medicines that remove glucose from the body via the kidneys.

    Additional Information

    For additional information regarding Xigduo XR or the improvement of glycemic control in adults with type II diabetes, please visit www.astrazeneca.com

    Approval Date: 2014-10-01
    Company Name: AstraZeneca
    Back to Listings

    Upcoming Events

    • 23Mar

      Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

    • 26Apr

      MAGI's Clinical Research vConference — Spring 2021

    Featured Products

    • Regenerative Medicine – Steps to Accelerate Development : PDF

      Regenerative Medicine: Steps to Accelerate Development

    • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

      Clinical Trial Agreements: A Guide to Key Words and Phrases

    Featured Stories

    • InputinLights-360x240.png

      Seeking Patient Input Early Helps Ensure Minority Participation in Trials

    • Oncology-360x240.png

      Global Oncology Trial Launches Drop Dramatically During Pandemic, Study Shows

    • Qualification-360x240.png

      Sites and Sponsors Streamlining Qualification Efforts with Technology, Process Revisions

    • New Algorithm Tested and Validated by CSDD Highly Predictive of Patient Burden

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell My Personal Information

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing